Nexalin Technology Reports Persistent Going Concern, Nasdaq Delisting Threat, and Material Weaknesses; Secures $756K via ATM for Clinical Trial

summarizeSummary

Nexalin Technology, Inc. reported a persistent going concern warning, an ongoing Nasdaq delisting threat, and material weaknesses in internal controls, despite raising $756,000 through a dilutive ATM offering and committing $945,000 to a new clinical trial.

check_boxKey Events

• Persistent Going Concern Warning

  Management explicitly states that the company does not believe it has sufficient cash and cash equivalents to satisfy anticipated cash requirements for the next twelve months, raising substantial doubt about its ability to continue as a going concern.

• Ongoing Nasdaq Delisting Threat

  The company remains non-compliant with Nasdaq's $1.00 minimum bid price rule, having received a deficiency letter on January 21, 2026, with a compliance period extending until July 20, 2026.

• Material Weaknesses in Internal Controls Persist

  The company reported continued material weaknesses in internal control over financial reporting related to a lack of sufficient resources for segregation of duties and insufficient IT controls.

• Significant Dilutive Capital Raise via ATM Program

  During the three months ended March 31, 2026, Nexalin Technology sold 1,395,300 shares of common stock under its ATM program for net proceeds of approximately $756,000. As of March 31, 2026, approximately $2,850,000 remains available under the program.

auto_awesomeAnalysis

This quarterly report reveals Nexalin Technology, Inc. is in severe financial distress, reiterating a going concern warning and stating that management does not believe it has sufficient cash for the next twelve months. The company continues to face a Nasdaq delisting threat due to non-compliance with the minimum bid price rule, with a compliance deadline of July 20, 2026. Furthermore, material weaknesses in internal controls persist, indicating ongoing operational and financial reporting risks. While the company raised $756,000 through its At-The-Market (ATM) program during the quarter, providing a temporary liquidity boost, this capital raise is highly dilutive and does not resolve the fundamental liquidity issues. The subsequent event of committing $945,000 to a pivotal clinical trial for its HALO Clarity device, while a positive step for product development, adds significant pressure to the company's already strained cash resources. Investors should be highly concerned about the company's ability to continue operations and maintain its listing.